Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04774315 · ClinicalTrials.gov registry record · Phase 4
Molecular Endotypes of Chronic Idiopathic Urticaria
A Phase 4 study of Chronic Urticaria, Idiopathic, sponsored by University of Colorado, Denver.
- Active
- Registry status
- Phase 4
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT04774315 is a Phase 4 study of Chronic Urticaria, Idiopathic that is active but no longer recruiting, run by University of Colorado, Denver. The registered enrollment target is 15 participants. The trial reports 1 study location across 1 state.
The verdict
NCT04774315, a Phase 4 study of Chronic Urticaria, Idiopathic, is active but no longer recruiting, sponsored by University of Colorado, Denver.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
This study plans to learn more about why some people with Chronic Idiopathic Urticaria (CIU) respond to treatment with omalizumab (Xolair). It will test people before they receive treatment with omalizumab as part of standard of care, to see if there are differences in their blood and skin that can predict who responds to treatment.
Conditions Studied
Interventions
- DRUG Omalizumab
Study Locations (1)
Colorado
- University of Colorado Anschutz - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2022-01-01 |
| Est. Completion | 2025-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04774315
The ClinicalTrials.gov registry entry for NCT04774315 describes a study currently listed as active not recruiting, categorized as Phase 4. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Urticaria, Idiopathic appearing as the primary indexed condition, and to 1 intervention - of which Omalizumab is the first listed.
NCT04774315 reports 1 study location spanning 1 distinct geographic area - top geographies include Colorado.
Frequently Asked Questions
What is clinical trial NCT04774315 about?
NCT04774315 is a clinical study titled "Molecular Endotypes of Chronic Idiopathic Urticaria". This study plans to learn more about why some people with Chronic Idiopathic Urticaria (CIU) respond to treatment with omalizumab (Xolair). It will test people before they receive treatment with omalizumab as part of standard of care, to see if there are differences in their blood and skin that can ...
What is the current status of trial NCT04774315?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 15 participants. The study started on 2022-01-01. Estimated completion is 2025-03.
What conditions does trial NCT04774315 study?
This clinical trial studies the following conditions: Chronic Urticaria, Idiopathic.
What interventions are being tested in trial NCT04774315?
The interventions under investigation include: Omalizumab (DRUG).
Who is sponsoring clinical trial NCT04774315?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04774315 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.